Page last updated: 2024-08-05 12:25:37
ent-kaurane diterpenoid
A diterpenoid compound having an ent-kaurane skeleton.
ChEBI ID: 36760
Members (6)
Member | Definition | Role |
---|---|---|
16beta,17-dihydroxy-ent-kaurane-19-oic acid | A ent-kaurane diterpenoid that is ent-kaurane-19-oic acid substituted by hydroxy groups at positions 16 and 17 (the 16beta stereoisomer). It is isolated from Helianthus sp. and Annona squamosa and exhibits anti-HIV activity. | 16beta,17-dihydroxy-ent-kaurane-19-oic acid |
atractyligenine | A diterpenoid isolated from coffee silverskin. It inhibits cutaneous photoaging. | atractyligenin |
kaurenoic acid | An ent-kaurane diterpenoid that is ent-kauran-19-oic acid in which a double bond is present at position 16(17); exhibits anticancer and anti-HIV 1 activity. | ent-kaur-16-en-19-oic acid |
oridonin | An organic heteropentacyclic compound and ent-kaurane diterpenoid with formula C20H28O6 isolated from the leaves of the medicinal herb Rabdosia rubescens. | oridonin |
steviol | An ent-kaurane diterpenoid that is 5beta,8alpha,9beta,10alpha-kaur-16-en-18-oic acid in which the hydrogen at position 13 has been replaced by a hydroxy group. | steviol |
stevioside | A diterpene glycoside that is rubusoside in which the hydroxy group at position 2 of the allylic beta-D-glucoside has been converted to the corresponding beta-D-glucoside. It is a natural herbal sweetener that is 250-300 times sweeter than sucrose (though with a bitter aftertaste), extracted from the Stevia rebaudiana plant native to South America. | stevioside |
Research
Studies (615)
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 20 (3.25) | 18.7374 |
1990's | 42 (6.83) | 18.2507 |
2000's | 98 (15.93) | 29.6817 |
2010's | 313 (50.89) | 24.3611 |
2020's | 142 (23.09) | 2.80 |
Study Types
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 15 (1.99%) | 5.53% |
Reviews | 53 (7.02%) | 6.00% |
Case Studies | 1 (0.13%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 686 (90.86%) | 84.16% |